Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)

Oncocyte Corp, referred to as OCX on the stock exchange, is a prominent player in the healthcare and life science industry. The company specializes in the development and commercialization of molecular technologies for oncology and transplantation research and diagnostics. Through a series of acquisitions, Oncocyte Corp has built a portfolio of proprietary technologies, including DetermaRx, DetermaIO, VitaGraft, and DetermaCNI. These technologies aid in identifying patients who will benefit from new, targeted treatments and therapies, and provide insights for physician decision-making.

Oncocyte Corp's main business activities revolve around the development and commercialization of diagnostic tests for oncology and transplantation. The DetermaRx test, a first-of-its-kind test, predicts patient risk of cancer recurrence following surgery and response to chemotherapy in early-stage lung cancer. The test has been commercialized and reimbursed by Medicare, and has demonstrated utility in multiple clinical studies.

The DetermaIO test is a gene expression-based test that assesses the tumor microenvironment and identifies patients whose immune system is poised to benefit from immunotherapy. The test has been shown to provide incremental utility beyond established biomarkers used to identify patients who will respond to immunotherapy. The test is differentiated from other approaches in that it measures the activity of genes expressed in immune effector cells, genes expressed in activated wound response cells, and in some cases, genes expressed by the tumor itself.

The VitaGraft test is a blood-based monitoring technology that provides physicians with a secondary data point to assess the effectiveness of therapy in patients with solid organ transplants. The test converts cell-free DNA next-generation sequencing results into a proprietary genome-wide copy number instability score, which can be used to monitor and guide ongoing treatment decisions.

The DetermaCNI test is a blood-based monitoring technology that provides physicians with a secondary data point to assess the effectiveness of therapy in patients with cancer. The test measures changes across the whole genome broadly, as opposed to changes in a subset of genes, and is applicable in both adjuvant and neo-adjuvant patient scenarios.

Oncocyte Corp operates a CLIA-certified laboratory in Nashville, Tennessee, and a research and development facility in Göttingen, Germany. The company's scientific foundation and unique approach to its technologies set it apart from its competitors, enabling it to compete effectively in the market.

The company's competitive position is based on its ability to successfully complete clinical studies, obtain regulatory approval, and market its tests effectively. Oncocyte Corp competes with multiple biomarkers already in clinical use or in development for predicting response to immunotherapy, as well as with tumor-informed tests that are on the market for treatment monitoring.

The company's customers include researchers and physicians in the oncology and transplantation fields, as well as pharmaceutical companies and biotechnology companies that are developing immunotherapies and other treatments for cancer and other diseases.

Oncocyte Corp's brand names and/or trade names of its products and services include DetermaRx, DetermaIO, VitaGraft, and DetermaCNI. These proprietary technologies are designed to help identify patients who will benefit from new, targeted treatments and therapies, and to provide insights for physician decision-making.